Jeetinder Singh Mahal - Mar 12, 2024 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Role
Chief Operating Officer
Signature
/s/ Jeet Mahal
Stock symbol
JSPR
Transactions as of
Mar 12, 2024
Transactions value $
-$17,402
Form type
4
Date filed
3/12/2024, 09:33 PM
Previous filing
Feb 20, 2024
Next filing
Jun 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JSPR Voting Common Stock Options Exercise $6.39K +900 +3.6% $7.10 25.9K Mar 12, 2024 Direct F1, F2
transaction JSPR Voting Common Stock Sale -$23.8K -900 -3.47% $26.44 25K Mar 12, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JSPR Stock Option (right to buy) Options Exercise $0 +900 +5.78% $0.00 16.5K Mar 12, 2024 Voting Common Stock 900 $7.10 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
F2 Effective on January 4, 2024, the Issuer conducted a reverse stock split of its voting common stock at a ratio of 1-for-10 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.79, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F4 The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split.
F5 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.